Drug Trial Radar · NCT06925581
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Apr 24, 2025
Primary completion
Apr 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
HRS-6768Drug
HRS-6768
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1:Dose-limiting toxicity (DLTs)Time frame: From first dose of study drug through at least 6 weeks
- Phase 1: recommended Phase 2 dose (RP2D)Time frame: From first dose of study drug to end of phase 1 treatment (up to approximately 1 years)
- Phase 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) of HRS-6768Time frame: From first dose of study drug to end of treatment (up to approximately 2 years)
- Phase 2: Progression-free survival (PFS)Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Gaobo Hospital
Beijing, Beijing Municipality, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.